Jupiter Neurosciences, Inc. (JUNS)Healthcare | Biotechnology | Jupiter, United States | NasdaqCM
4.18 USD
-0.71
(-14.519%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.10 -1.08 (-1.079%) ⇩ (Aug. 28, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:37 a.m. EDT
The immediate outlook is severely clouded by a catastrophic breakdown in price structure, where the stock recently collapsed from a fifty-two-week high of $138 to a mere $6.20, followed by a volatile, low-price trading range. This massive gap between historical highs and current levels, combined with a negative statistical forecast and heavy volume relative to average, suggests a strong short-term bearish bias as the market digests the reality of the situation. However, the long-term investment case is effectively nonexistent due to deteriorating fundamentals; the company reports negative earnings, negative book value, and a balance sheet that is barely solvent with a current ratio below 0.7 and significant debt. While recent news highlights a $2 million capital raise and a licensing deal for ALA-002, these events are insufficient to offset the structural damage of a multi-year decline and the lack of organic revenue growth. Furthermore, there is no dividend income to provide any cushion, making this a speculative vehicle rather than an investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 1.386892 |
| AutoETS | 1.387092 |
| MSTL | 1.389029 |
| AutoTheta | 1.460824 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 15% |
| H-stat | 685.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.038 |
| Excess Kurtosis | -1.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.13 |
| Market Cap | 5,511,417 |
| Forward P/E | 69.67 |
| Website | https://jupiterneurosciences.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9520588 |
| Address1 | 1,001 North US Highway 1 |
| Address2 | Suite 504 Palm Beach Gardens |
| All Time High | 1,463.25 |
| All Time Low | 4.56 |
| Ask | 5.35 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 5,379,520 |
| Average Daily Volume3 Month | 991,079 |
| Average Volume | 991,079 |
| Average Volume10Days | 5,379,520 |
| Bid | 5.33 |
| Bid Size | 20 |
| Book Value | -0.551 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.18 |
| Current Ratio | 0.657 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.15 |
| Day Low | 4.101 |
| Display Name | Jupiter Neurosciences |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 61.721 |
| Enterprise Value | 3,992,898 |
| Eps Forward | 0.06 |
| Eps Trailing Twelve Months | -18.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.7405 |
| Fifty Day Average Change | -6.5605006 |
| Fifty Day Average Change Percent | -0.6108189 |
| Fifty Two Week Change Percent | -95.20588 |
| Fifty Two Week High | 138.0 |
| Fifty Two Week High Change | -133.82 |
| Fifty Two Week High Change Percent | -0.9697102 |
| Fifty Two Week Low | 4.101 |
| Fifty Two Week Low Change | 0.078999996 |
| Fifty Two Week Low Change Percent | 0.019263593 |
| Fifty Two Week Range | 4.101 - 138.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,733,236,200,000 |
| Float Shares | 550,231 |
| Forward Eps | 0.06 |
| Forward P E | 69.666664 |
| Free Cashflow | -3,261,390 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.71 |
| Fullday Change Percent | -14.5194 |
| Fullday Price | 3.1006 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,818,864 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19969 |
| Held Percent Institutions | 0.02428 |
| Implied Shares Outstanding | 1,318,521 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-12-03 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,786,060,800 |
| Last Split Factor | 1:75 |
| Long Business Summary | Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. |
| Long Name | Jupiter Neurosciences, Inc. |
| Market | us_market |
| Market Cap | 5,511,417 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_374998760 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -9,199,420 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,421,197 |
| Open | 5.15 |
| Operating Cashflow | -7,249,495 |
| Operating Margins | -113.13446 |
| Payout Ratio | 0.0 |
| Phone | 561 406 6154 |
| Post Market Change | -1.0793998 |
| Post Market Change Percent | -25.822962 |
| Post Market Price | 3.1006 |
| Post Market Time | 1,787,961,299 |
| Previous Close | 4.89 |
| Price Hint | 4 |
| Price To Book | -7.5862064 |
| Price To Sales Trailing12 Months | 85.193405 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.395 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.71 |
| Regular Market Change Percent | -14.5194 |
| Regular Market Day High | 5.15 |
| Regular Market Day Low | 4.101 |
| Regular Market Day Range | 4.101 - 5.15 |
| Regular Market Open | 5.15 |
| Regular Market Previous Close | 4.89 |
| Regular Market Price | 4.18 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 204,251 |
| Return On Assets | -1.59558 |
| Return On Equity | -18.88703 |
| Revenue Per Share | 0.13 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,318,521 |
| Shares Percent Shares Out | 0.0385 |
| Shares Short | 29,679 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,188 |
| Short Name | Jupiter Neurosciences, Inc. |
| Short Percent Of Float | 0.0505 |
| Short Ratio | 0.11 |
| Source Interval | 15 |
| State | FL |
| Symbol | JUNS |
| Total Cash | 1,521,874 |
| Total Cash Per Share | 1.976 |
| Total Debt | 1,749,076 |
| Total Revenue | 64,693 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -18.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 39.2555 |
| Two Hundred Day Average Change | -35.0755 |
| Two Hundred Day Average Change Percent | -0.8935181 |
| Type Disp | Equity |
| Volume | 204,251 |
| Website | https://jupiterneurosciences.com |
| Zip | 33,477 |